BRCA1 and cancer: The PARP inhibitors such as olaparib are also more efficacious in treating patients with homologous double-stranded DNA-repair (58), the primary impairment mechanism of cancers associated with BRCA mutations (59), further justifying our strategy for BRCA1/2 testing.